Qingdao Baheal Medical INC.

Qingdao Baheal Medical INC.

301015 · SHE · Healthcare / Medical Distribution

25.06CNY-1.94 (-7.19%)

Price History

Full chart

Market Stats

Previous Close27.00
Open25.53
Day Range25.02 – 26.50
52-Week Range18.40 – 28.40
Volume15.11M
Market Cap13.50B
P/E (TTM)25.68
Forward P/E0.00
EPS1.00
Dividend Yield2.22%
Beta0.20
50-Day Avg24.39
200-Day Avg23.43

About

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical nutrition under the Nutrasumma brand name, as well as skincare under the Cactus brand name. In addition, the company offers ZAP-X, an AI radiosurgery robot for intracranial tumors and lesions; Cifu VAD, the fully magnetically levitated ventricular assist device; and AtriCure Bipolar Radiofrequency Ablation Isolator for the treatment of chronic atrial fibrillation. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of Baiyang Pharmaceutical Group Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryMedical Distribution
  • CEOMr. Gang Fu
  • Employees2.49K
  • HeadquartersBuilding 1, No. 88 Tongbai Road, Qingdao, China, 266042, China
  • Websitehttps://www.baheal.cn

Leadership

  • Mr. Gang FuChairman & GM · b. 1970
  • Mr. Zhen LiFinancial Director, Secretary, Director & Deputy GM · b. 1982
  • Mr. Xiaowei ZhuDeputy GM & Director · b. 1963
  • Ms. Yuan ZhangDeputy General Manager · b. 1975
  • Mr. Ting Wei WangDeputy General Manager · b. 1978
  • Ms. Bi Quan WangDeputy General Manager · b. 1962
  • Feng LiuHead of the Accounting Department & Accounting Supervisor

Financials

Income Statement

Currency: CNY2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.39B3.03B3.10B3.65B4.85B5.88B7.05B7.51B8.26B8.09B7.51B
Growth (%)-+26.85%+2.02%+17.99%+32.75%+21.26%+19.94%+6.50%+9.94%-1.96%-7.26%
Cost of Revenue1.61B2.01B2.06B2.45B3.50B4.42B5.28B5.43B5.51B5.23B4.69B
Gross Profit781.74M1.02B1.04B1.20B1.35B1.46B1.77B2.08B2.75B2.87B2.81B
Gross Margin32.68%33.61%33.56%32.83%27.84%24.90%25.16%27.75%33.32%35.41%37.47%
Operating Expense714.21M800.24M792.67M885.07M1.05B1.10B1.21B1.41B1.71B1.89B2.01B
Operating Income67.53M219.56M246.25M314.19M296.05M368.00M561.48M674.26M1.04B977.74M805.15M
Operating Margin2.82%7.24%7.95%8.60%6.11%6.26%7.96%8.98%12.64%12.08%10.73%
EBITDA89.00M240.74M294.44M400.12M368.76M455.89M653.25M754.24M1.15B1.10B945.69M
EBITDA Margin3.72%7.93%9.51%10.95%7.61%7.75%9.26%10.04%13.93%13.59%12.60%
Net Income72.87M184.02M221.98M258.10M209.87M272.71M421.64M502.09M712.06M691.59M474.69M
Net Income Margin3.05%6.06%7.17%7.07%4.33%4.64%5.98%6.69%8.62%8.54%6.32%
R&D------05.35M42.45M36.14M42.17M
R&D as % of Total Revenue------0.00%0.07%0.51%0.45%0.56%
Interest Expense---43.15M58.81M65.41M65.98M62.36M64.03M81.86M103.65M
Interest Expense % of Total Revenue---1.18%1.21%1.11%0.94%0.83%0.78%1.01%1.38%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--2.63B3.43B4.05B4.60B5.12B6.42B7.11B8.11B
Total Liabilities--1.54B2.12B2.55B2.43B2.84B3.30B4.51B5.37B
Total Equity--1.08B1.28B1.47B2.16B2.30B2.89B2.37B2.46B
Cash--785.23M1.16B1.11B1.28B1.05B1.34B1.47B2.14B
Total Debt--883.10M1.35B1.38B1.23B1.34B1.45B2.31B-
Net Debt--97.87M184.36M242.78M-50.00M289.94M110.13M846.30M1.05B

Cash Flow

Currency: CNY2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow55.50M45.96M-116.83M181.30M305.75M799.50M813.85M934.45M
Investing Cash Flow-69.98M701.26K-42.63M-22.82M-117.33M-295.71M-732.32M-
Financing Cash Flow-99.76M239.29M305.81M38.04M-543.58M-333.20M4.67M-
Capital Expenditure15.74M2.95M16.35M27.49M105.32M185.49M303.99M288.93M
Free Cash Flow39.76M43.01M-129.71M153.81M200.43M614.01M509.86M645.52M
Dividends Paid-50.20M148.91M55.72M350.24M440.11M449.86M467.57M
FCF to OCF71.64%93.57%111.02%84.84%65.55%76.80%62.65%69.08%
Dividend Paid to FCF-116.73%-114.81%36.23%174.75%71.68%88.23%72.43%

Earnings

Report DateSep 30, 2021Dec 31, 2021Apr 26, 2022Aug 17, 2022Oct 28, 2022Dec 31, 2022Apr 24, 2023Aug 28, 2023Oct 26, 2023Dec 31, 2023Apr 22, 2024Jun 30, 2024Oct 25, 2024Dec 31, 2024Apr 23, 2025Jun 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate------------------
EPS Actual0.230.220.170.240.250.300.230.340.350.290.310.370.500.100.160.15-0.000.24
Surprise------------------
Timing--Pre-marketAfter-hoursPre-market-Pre-marketAfter-hoursPre-market-Pre-market-Pre-market-Pre-market---

Key Statistics & Ratios

Market Cap13.50B
Enterprise Value15.38B
Trailing P/E25.68
Forward P/E0.00
Price / Sales1.85
Price / Book5.73
EPS1.00
Book Value4.56
Revenue (TTM)7.31B
Gross Profit (TTM)2.84B
EBITDA829.92M
Profit Margin7.33%
Operating Margin9.41%
Return on Equity24.76%
Return on Assets6.30%
Shares Outstanding525.62M
Shares Float130.84M
Beta0.20
Dividend Yield2.22%
Dividend Rate0.57
Payout Ratio2.46%

Dividends

20261×
0.57Jun 1, 2026
20251×
0.76May 27, 2025
20241×
0.76May 29, 2024
20231×
0.76May 25, 2023
20221×
0.67May 25, 2022